Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

February 29, 2012

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

labetalol/hydralazine/enalapril

Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).

Trial Locations (4)

Unknown

University of Calgary, Calgary

University of Ottawa, Ottawa

T6G2B7

University of Alberta, Edmonton

T6L 5X8

Grey Nuns Hospital, Edmonton

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

collaborator

Alberta Heritage Foundation for Medical Research

OTHER

lead

University of Alberta

OTHER

NCT00963976 - Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial | Biotech Hunter | Biotech Hunter